What actually happens at 5 months on Wegovy

Step 1: how you got to month five, the dose ladder to here

Wegovy's titration schedule is deliberate. Treatment opens at 0.25mg, a dose that exists purely to let your system adjust, then steps through 0.5mg, 1.0mg and 1.7mg before reaching the standard 2.4mg maintenance level. Each step takes roughly four weeks, which means most people only arrive at the full maintenance dose around week sixteen or seventeen. If you have been on Wegovy for five months, you have probably had between six and eight weeks at 2.4mg, long enough for the appetite effects to feel settled, but still early in the maintenance phase.

The two-month mark is often when the dose increases start feeling significant; by month four many people are consolidating. Month five is, for most, the first sustained stretch where nothing is changing week to week. That stability is both the goal and, sometimes, the reason progress feels less visible than it did at the start.

If the 7.2mg higher-dose pen is something your prescriber has discussed, it would not typically come into consideration until the standard maintenance course has been assessed, a decision made clinically, not by the patient. The full semaglutide overview covers the approved dose range and the MHRA's April 2026 approval of the dedicated 7.2mg pen.

Step 2: what weight loss normally looks like at this stage

A question our prescribers hear most weeks around this point: "My weight loss has slowed, is something wrong?" It almost never is. The fast early losses in months one and two reflect a combination of caloric deficit, water shifts and the strong novelty of appetite suppression. By month five, energy intake has often stabilised at its new lower level, which means the deficit narrows and so does the rate of loss.

The STEP 1 clinical trial, published in the New England Journal of Medicine, recorded an average body-weight reduction of around 15% at 68 weeks for participants on semaglutide 2.4mg alongside lifestyle changes. Month five, at roughly twenty weeks, sits before the peak loss period, most of the total reduction in that trial accrued across the full 68 weeks, not just the early months. Steady progress at this stage is not a plateau; it is the treatment working as designed.

If weight has genuinely stalled for six or more weeks at the maintenance dose, that warrants a prescriber conversation. The six-month milestone is often when clinical teams review whether continuing at the current dose is appropriate, per NICE guidance for semaglutide.

Step 3: managing side effects that linger or appear late

Nausea, constipation and reflux are most common in the first eight weeks. For most people they ease considerably by the time the maintenance dose is established. At five months, persistent GI symptoms or new ones appearing after a settled period are worth flagging to your prescriber rather than managing alone.

The MHRA updated its guidance on GLP-1 medicines in January 2026, highlighting acute pancreatitis as an infrequent but serious potential effect. The signal to act is severe stomach pain, particularly pain that radiates toward the back, with or without vomiting, seek urgent medical attention if that happens. You can report any suspected side effect through the Yellow Card scheme, which covers both medicines and any suspect supply you've encountered.

For a broader look at what semaglutide side effects tend to look like across the treatment course, the NHS semaglutide page sets out the full list in plain language. Fatigue, headaches and injection-site reactions are also reported, though less frequently than the GI effects at this stage.

Step 4: what month five means for planning what comes next

Month five is a useful moment to take stock. NICE's recommendation for semaglutide (TA875) includes a review at six months on the maintenance dose: if weight loss is below 5%, clinical guidance suggests reconsidering whether treatment should continue. That review is a conversation with your prescriber, not a self-assessment.

It is also the point where some people start asking about cost across a longer course. Understanding what private treatment involves financially is a legitimate question at this stage, our treatment overview covers how pricing is structured for ongoing private access, and what the one transparent price includes beyond the medicine itself.

People who started treatment thinking five months would be the finish line often find it is closer to the mid-point of a sustained approach. The three-month experience and the semaglutide trajectory at three months give useful comparison points if you want to trace how this stage relates to earlier ones. For those considering whether Wegovy remains the right choice at this point, our prescribers can discuss your progress and options, start with a free consultation at our treatment page.